The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The use of targeted drug therapy for aggressive lymphoma
Mariana Bastos, MD, PhD, Gregorio Marañón University General Hospital, Madrid, Spain, discusses advancements in targeted therapies for aggressive lymphoma. She highlights early-line treatments combining novel cereblon E3 ligase modulators (CELMoDs) or atezolizumab with the R-CHOP regimen. In the relapsed/refractory (R/R) setting, she notes the combinations of glofitamab with a novel CD19/4-1BB T-cell engager and epcoritamab with polatuzumab vedotin-R-CHP (pola-R-CHP). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, Astra-Zeneca, BMS/Celgene, Incyte, Kite, Novartis, Roche, Takeda; Research Funding: Roche, Kite, AMHH, SEHH, IiCIII; Honoraria: Abbvie, BMS/Celgene, Incyte, Kite, Novartis, Roche, Takeda.
